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Franche-Comté et CHU Dijon-Bourgogne, Dijon, France, 7 Department of Public Health, Clinical and
Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy, 8 School of Nursing
and Human Science, Dublin City University, Glasnevin, Dublin, Ireland, 9 Cancer Epidemiology and
Genetics, Masaryk Memorial Cancer Institute and MF MU, Brno, Czech Republic, 10 Centre of Chronic
Immunodeficiency, Molecular Epidemiology, University Medical Center Freiburg, Freiburg, Germany,
11 Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount
Sinai, New York, NY, United States of America, 12 IARC, International Agency for Research on Cancer,
Lyon, France
☯ These authors contributed equally to this work.
* elisa.pasqual@isglobal.org
Abstract
Medical diagnostic X-rays are an important source of ionizing radiation (IR) exposure in the
general population; however, it is unclear if the resulting low patient doses increase lym-
phoma risk. We examined the association between lifetime medical diagnostic X-ray dose
and lymphoma risk, taking into account potential confounding factors, including medical his-
tory. The international Epilymph study (conducted in the Czech-Republic, France, Germany,
Ireland, Italy, and Spain) collected self-reported information on common diagnostic X-ray
procedures from 2,362 lymphoma cases and 2,465 frequency-matched (age, sex, country)
controls. Individual lifetime cumulative bone marrow (BM) dose was estimated using time
period-based dose estimates for different procedures and body parts. The association
between categories of BM dose and lymphoma risk was examined using unconditional
logistic regression models adjusting for matching factors, socioeconomic variables, and the
presence of underlying medical conditions (atopic, autoimmune, infectious diseases, osteo-
arthritis, having had a sick childhood, and family history of lymphoma) as potential con-
founders of the association. Cumulative BM dose was low (median 2.25 mGy) and was not
positively associated with lymphoma risk. Odds ratios (ORs) were consistently less than 1.0
in all dose categories compared to the reference category (less than 1 mGy). Results were
similar after adjustment for potential confounding factors, when using different exposure
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scenarios, and in analyses by lymphoma subtype and by type of control (hospital-, popula-
tion-based). Overall no increased risk of lymphoma was observed. The reduced ORs may
be related to unmeasured confounding or other sources of systematic bias.We found little
evidence that chronic medical conditions confound lymphoma risk and medical radiation
associations.
Introduction
The use of ionizing radiation (IR) in medicine has significantly improved patient care. How-
ever, it has also resulted in a large increase in IR exposure to the general population [1–3], thus
raising concerns in the public health and radiological protection communities. Medical diag-
nostic procedures typically deliver low to moderate IR doses. Estimating risk of lymphoma at
these low dose levels represents a challenge for epidemiology. Lymphomas are mainly classi-
fied into Hodgkin Lymphomas (HL) and Non Hodgkin Lymphomas (NHL), and are initiated
by a mutation in a lymphoid stem cell. Lymphoid cells originate in the bone marrow (BM), a
radiosensitive organ; at present, it is unclear whether IR increases the risk of lymphoma risk,
particularly at low doses [4–7].
Table 1 summarizes results of major studies of lymphoma risk and low-dose IR exposure.
In studies of atomic bomb survivors, the incidence of malignant lymphoma and mortality of
NHL were both positively associated with radiation exposure in men, but not in women [8, 9].
In the largest combined analysis of nuclear workers studies, a non-statistically significant
increased risk was found for both HL and NHL mortality [10]. An increase in NHL incidence
was also observed in Chernobyl liquidators [11]. Results of previous studies of medically-
exposed subjects are mixed and unclear. There was no positive association of NHL and medi-
cal diagnostic radiation exposure in two studies in the US and Australia [12, 13]. Similarly, no
increased HL risk from pediatric Computer Tomography (CT)-scan exposure [14] was found
in the UK, though an Australian CT-cohort reported a significant increase in risk when com-
paring subjects exposed to CT-scans to those unexposed [13].
Among NHL subtypes, chronic lymphocytic leukemia (CLL) has traditionally been thought
not to be radiation-induced, based on lack of evidence of an increased risk in studies of atomic
bomb survivors. However, CLL is very rare in Japan and has a long asymptomatic period,
hence the study of atomic bomb survivors has low statistical power to detect an increased risk,
if any [21]. Increases in the risk of CLL have been noted in a number of nuclear workers stud-
ies [19] as well as among Chernobyl clean-up workers (liquidators) [11, 17] and recently also
in the atomic bomb survivors incidence follow-up [8]. Thus, the question of whether or not
CLL can be induced by radiation is still under debate [19].
A potential concern in estimating lymphoma risk from medical radiation exposure is possi-
ble confounding by clinical indication. Medical radiation exposure does not occur at random
in the general population; rather, it tends to be related to a person’s underlying medical his-
tory. Furthermore, patients with lymphoma tend to share a particular pattern of medical his-
tory: they are more likely to suffer from immune deficiencies or infectious diseases (hepatitis B
or mononucleosis), and less likely to have an atopic disease [6, 22, 23]. Previous studies of lym-
phoma risk in relation medical radiation exposure have generally not considered these poten-
tial confounding factors [12–14].
Here we examine the association between medical diagnostic IR exposure and lymphoma
risk in the multicentre European lymphoma case-control study Epilymph. For this, we
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Table 1. Summary of previous studies evaluating lymphoma risk after ionizing radiation exposure.
Reference Study design and description of
the population
Exposure details Results Conclusions
Outcome = Malignant lymphoma (combining NHL and HL)
[9] Mortality—A-bomb survivors
cohort study–follow-up to 2003
(N = 120321; 284 lymphoma
cases)
Bone marrow dose, Range 0 to 4Gy ERR/10 mGya 0.0016, 95% CI
(-0.0013; 0.027)
No increased risk of lymphoma mortality
overall. Increase in men but not in women,
possibly reflecting a disparity in lymphoma
subtypes by gender.
ERR/10 mGya 0.007, 95% CI
(0.0008; 0.017) in males
ERR/10 mGya -0.0018, 95%CI
(-0.0021; 0.0024) in females
[15] Mortality—A-bomb survivors
cohort study–follow-up to 2000
male aged 16–64 at time of
bombing (N = 20940; 90
lymphoma cases)
Radiation dose absorbed by the
colonb, Range 0 to 4 Sv
ERR/ 10 mSvc 0.0079, 90% CI
(0.001; 0.0188), 5 year lag
Evidence of an increased risk
Mortality—Savannah River Site
(SRS) US nuclear weapons
worker cohort study (N = 15264;
56 lymphoma cases)
Occupational; Cumulative whole
body radiation, 0–0.5 Sv
ERR/10 mSvc 0.0699 90%CI
(0.0096; 0.1839)
Evidence of an increased risk
[16] Incidence—Cohort of children/
adolescent undergoing a cardiac
catheterization procedure
(N = 11270; 22 lymphoma cases)
Medical procedures (cardiac
catheterization and CT-scan);
cumulative bone marrow radiation:
median 3.1; p25 1.3 and p75 9.3 mGy
SIR for lymphoma 9.15 95% CI
(5.66–13.97) with 2 years lag
period
Lymphoma rate among patients receiving
cardiac catheterization is high compared
with general population. It is likely that
transplant (immunodepressive medication)
is the most likely causal factor.
Outcome = Non Hodgkin Lymphoma
[8] Incidence–A-bomb survivors
cohort study–follow-up 1950–
2001 [N_ = 113,011; 402 NHL]
Bone marrow dose, Range 0 to 4 Sv ERR/10 mGy 0.0046, 95% CI
(-0.0008; 0.0129) in males
Weak support for an association between
radiation and NHL in men
ERR/10 mGy 0.0002, 95% CI
(-0.0044; 0.0064) in females
[10] Mortality—INWORKS study,
nuclear industry workers from
US, France, UK [N = 113,011 and
710 NHL]
Occupational; cumulative lifetime
bone marrow dose, Mean(range), 15.9
(0–1217.5) mGy
ERR/10 mGy 0.0047, 90%CI
(-0.0076 to 0.02)
Positive but non significant association.
[11] Case-control study of
hematological malignancies (20
NHL / 80 controls) in Chernobyl
liquidators
Bone marrow doses from work as a
clean-up worker. 78% < 50 mGy; 14%
> = 100 mGy.
ERR/10 mGy 0.281, 95% CI
(0.009; 2.43)
Increase risk of NHL after exposure to IR
[12] Lymphoma case-control study
(318 cases, 449 controls)—US
Medical diagnostic radiation;
cumulative lifetime bone marrow dose
(based on literature review). Dose not
reported. Category cut point are 1, 2,3
and 4 mGy
RR for the exposed versus
unexposed 0.99, 95% CI (0.6;
1.6); RR of the highest exposure
category versus lowest 1.4 (CI
not reported)
No statistically significant association
found
Outcome = Hodgkin Lymphoma
[8] Incidence–A-bomb survivors
cohort study follow-up 1950–
2001 [N = 113,011; 35 HL]
Bone marrow dose, Range 0 to 4 Sv ERR/10 mGy 0.002, 95% CI
(-0.0103; 0.0263)
No evidence for an increased risk
Small number of cases
[10] Mortality—INWORKS study,
nuclear industry workers from
US, France, UK [308,297 cohort
size; 104 HL cases]
Occupational; cumulative bone
marrow dose, Mean(range), 15.9 (0–
1217.5) mGy
ERR/10 mGy 0.0294, 95% CI (n.
e; 0.1149)
Positive but not significant association,
Small number of cases
[14] UK cohort of CT-scan exposed
children [178,601 cohort size; 65
HL cases];
CT-scan exposure; cumulative bone
marrow dose (mean 11 mGy, range
0–689 mGy)
ERR/10 mGy 0.02, 95% CI
(-0.16; 0.21), 2 year lag-period,
Bone marrow dose
No association, Small number of cases
CT-scan exposure; cumulative
lymphoid dose (mean 8mGy, range
0–348 mGy).
ERR/10 mGy 0.28, 95% CI
(-0.24; 0.8), 2 year lag period
(Continued)
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estimated cumulative lifetime BM dose from the study participants’ self-reported medical
radiological histories. The exposure quantity used here was cumulative absorbed dose to the
BM, the quantity generally used in previous studies of lymphoma risk [8, 14]. We then
explored the association between lifetime BM dose and lymphoma risk taking into account the
potential confounding effect of medical history variables.
Table 1. (Continued)
Reference Study design and description of
the population
Exposure details Results Conclusions
[13] Australia, population based
cohort of CT exposed children
[10.939.680 cohort size; 228 HL]
CT-scan exposure; Exposed (680.211
people) vs Unexposed
IRR 1.15, 95%CI (1.01 to 1.32),
1 year lag-period
Risk increased, No dose estimate. Reverse
causation could also explain this result
(short lag-period)
Outcome = Chronic lymphocytic leukemia
[8] Incidence–A-bomb survivors
cohort study follow-up 1950–
2001 [N = 113,011; 12 CLL]
Bone marrow dose, Range 0 to 4 Sv Statistically significant linear
trend (P <0.05)
Suggest a possible increase in CLL, Small
number of cases
[10] Mortality data of INWORKS
study, nuclear industry workers
from US, France, UK [138 deaths]
Occupational; cumulative bone
marrow dose Mean(range), 15.9 (0–
1217.5) mGy
ERR/10 mGy -0.0106, 90% CI
(n.e.; 0.0181)
No association
[17] Nested case-control study of
Ukraine clean-up workers of
Chernobyl accident (cohort size
110,645; 65 CLL cases)
Bone marrow doses from work as a
clean-up worker. Mean (SD) of
cumulative BM dose 132.3 (342,6)
mGy in cases and 81.8 (193,7) mGy in
controls
ERR/10 mGy 0.0258, 95% CI
(0.0002; 0.0843)
Increased risk of CLL
[11] Case-control study of
hematological malignancies (21
CLL / 80 controls) in Chernobyl
liquidators
Bone marrow doses from work as a
clean-up worker. 78% < 50 mGy; 14%
> = 100 mGy.
ERR/10 mGy 0.047, 90% CI (n.
e.; 0.76)
Non-significantly increased risk of CLL
associated with radiation exposure, Small
number of cases
[18] Nuclear worker study (15-country
study; 295,963 workers), mortality
analysis (65 CLL deaths)
Occupational; cumulative bone
marrow dose, Mean 14.7 mSv
RR at 100 mSv compared to 0
mSv: 0.84, 95% CI (0.39, 1.48)
No association. Few CLL deaths
[19] Nested case-control study of
worker of US nuclear weapon
facilities (94517 cohort size; 43
deaths and 172 controls)
Occupational, lifetime cumulative
bone marrow dose + work-related
medical X-ray exposure. Median dose
in cases was 1.4 mSv
ERR/10mSvc -0.020, 95% CI (n.
e. to 0.14). No CLL case above
100 mSv.
Little evidence for an association, Small
number of deaths
ERR/10mSvc excluding subjects
with dose above 100 mSvc 0.16,
95% CI (-0.044; 0.83)
[20] Case-cohort study in 23,043
uranium miners (53 CLL cases)
Occupational radon exposure, (using
industry tables of mean annual 222Rn
concentrations)
RR for highest exposure
category compared to lowest
quintile of distributiond 1.98,
95% CI (1.1; 3.59)
Positive association between radon
exposure and CLL risk, Small number of
cases
[12] Lymphoma case-control study
(207 cases, 449 controls)—US
Lifetime medical diagnostic
exposure; Exposed versus unexposed
Relative risk 2 year lag period
0.56 (0.3; 1.1 95%CI)
Negative non significant association.
Ascertainment bias could be an
explanation
ERR: Excessive Relative Risk; RR: Relative risk; IRR: Incidence Rate Ratio; CI: Confidence Interval; SIR: Standardized Incidence Ratio; n.e: not estimable.
aIn recent atomic bomb survivor studies, the doses are expressed as “weighted doses”, in Gy, rather than equivalent doses in Sv, using a weighting factor of 10 for
neutrons, whatever their energy.
bColon dose in atomic bomb survivors reports is usually used for solid cancer risk estimation.
cDose estimated in Sv because the study focused on high energy photon exposure; for comparison purposes 1 Gy of absorbed dose is approximately equal to 1 Sv of
equivalent dose.
dHighest category corresponds to 110 WLM or more; lowest category to less than 3 WLM. WLM: Working Level Month; a WLM is a unit of exposure defined as an
exposure to 1 Working Level (a measure of concentration of alpha particles in air) of radon for one month (170 hours).
https://doi.org/10.1371/journal.pone.0235658.t001
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Materials and methods
Study design
Epilymph is a case-control study of incident lymphoma conducted between 1998 and 2004 in
the Czech-Republic, France, Germany, Ireland, Italy, and Spain. Cases were recruited as soon
as possible after the diagnosis to minimize the possibility of any survival bias. Controls were
frequency matched by 5-year age groups, sex and country of residence and randomly selected
from population registries in Italy and Germany (population-based recruitment) and among
patients admitted to the same hospital as cases in the remaining countries (hospital-based
recruitment). The proportion of hospital-controls who had the same diagnosis for hospital
admission was kept lower than 10%. Participation consisted of an in-person interview on the
subject‘s socioeconomic status (SES), lifestyle factors and medical history, including medical
radiological history. Interviews were conducted by trained personnel using a structured ques-
tionnaire. The detailed methods have been published elsewhere [24, 25].
Exposure estimation
Regarding medical radiological history, the interviewer presented a list of common radio-diag-
nostic examinations: conventional X-ray to the thorax, abdomen (with and without contrast),
kidney, bones and face; dental X-ray; gammagraphy (not collected in Germany), and Comput-
erized Tomography (CT) scans. Participants were asked to report the total number of proce-
dures they underwent and the age at first and last procedure for each type of examination. The
precise body part was not asked for bone X-rays, CT-scans or gammagraphy. An additional
question about any additional examinations was asked, with the answer recorded as free text.
The list of questions asked can be found in S1 File.
We excluded examinations taken during the two years prior to the date of diagnosis/refer-
ence date to allow for an appropriate latency period between exposure and diagnosis as well as
to exclude any procedure possibly related to the diagnosis of the cases. As only age at first and
last procedures were available, we assumed a uniform distribution of examinations between
the two reported ages, excluding those that fell within the 2-year exclusion period. A sensitivity
analysis using a 5 year exclusion period was also performed. We excluded CT-scans reported
before the year 1980 (44 CT-scans reported by 42 subjects) since CT-scans were not routinely
performed until the late 1970´s-early 1980’s [26, 27].
Since there were no data on the specific dosimetry protocols followed for each procedure
and body part, we based our organ dose estimations on typical protocols used in different
decades, using published estimates of organ doses. This approach has been used in other simi-
lar studies [12, 13, 28]. For conventional X-rays, Melo [29] provided a dose value for each
10-year period from 1930 to 2010. For CT-scans, Kim et al. [30] provided a dose value by sex
for two different time periods (pre- and post-2001) and by year of age (0–22 years). We subse-
quently calculated a mean dose value for the following age groups: 0–5; 6–10; 11–15; 16–20;
and>20 years. Since no body part specification was available for CT-scans or bone X-rays, we
attributed to each body part a weighted average of doses to different anatomical regions,
according to the frequency of examinations of these regions in the general population [3, 31,
32]. A look-up table was derived to assign doses by type of procedure, body part, and time
period (see S1 and S2 Tables).
For the cumulative dose calculation, we excluded 169 gammagraphy procedures (reported
by 107 subjects) because of lack of information on the procedure in the study questionnaire,
and no information was collected in Germany. We also excluded 9,125 dental X-ray proce-
dures (reported by 2,296 subjects) since the fraction of BM in the mandible is close to 0 [33].
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Indeed, the dose to the bone marrow from one intraoral dental X-ray is estimated to range
from 10−3 to 10−5 mGy, depending on the time period [34]. An additional 52 examinations
reported in free text by 51 subjects were also excluded as they were too poorly defined to
classify.
Cumulative lifetime BM dose was calculated summing doses from all procedures up to the
exclusion period. As only age at first and last procedures was available, we attributed: a) to the
first and last procedures, the doses in the look-up table corresponding to the time periods and
type of procedures. Since there was no data on the precise time period for the remaining “n-2”
examinations, we used three different scenarios for attributing dose values, as follows: a) the
mean of the dose over the entire time period between first and last exposure for that type of
procedure (main analysis); b) the dose corresponding to the time period of the first procedure;
c) the dose corresponding to the time period of the last procedure. Therefore, for each partici-
pant and examination we estimated three possible dose values. Sensitivity analyses using the
“b” and “c” scenarios were conducted to compare results under the alternative exposure
assumptions. Total cumulative BM dose was then estimated for each scenario by summing
across all examination types (S2 File). Cumulative BM dose was categorized into 4 categories,
with cut points chosen a priori: 1, 5 and 15 mGy (which approximately correspond to the 25th,
75th and 95th percentiles of the dose distribution in the exposed controls).
Outcome definition
For all cases, diagnosis was histologically confirmed and classified according to the World
Health Organization (WHO) classification of neoplastic diseases revision 3 [35]. For the main
analysis we considered all lymphomas together. Additional analyses were conducted by sub-
type: NHL, HL and CLL. In addition an analysis with all lymphomas excluding CLL was per-
formed for consistency with previous radiation epidemiology papers [10].
Definition of covariates
Data on personal and family medical history were collected as part of the study interview by
asking if the subject or one of his/her family members had ever suffered from any of a number
of medical conditions and, if so, the age at onset. The conditions were grouped as follows: a)
family history of lymphoma; b) any autoimmune disease (arthritis, lupus, celiac disease and
rheumatic fever); c) any atopic disease (asthma, eczema, allergy, urticaria and sinusitis); d) any
infectious disease (mononucleosis, tuberculosis, hepatitis, brucellosis and typhoid fever); e)
osteoarthritis; f) cardiovascular disease (diabetes, hypertension). A measure of global health
status in childhood was also captured by asking the participants about their level of health dur-
ing childhood using five questions (having been more sick/absent from school comparing with
schoolmates; taking more medicines/antibiotics comparing with siblings; having been a very
healthy child) [25]. Two measures of Socio-Economic Status (SES) were also captured: a) years
of school attendance (categorized using cut points of: 10, 13 years); and b) socio-economic sta-
tus based on the Standard International Occupational Prestige Scale (SIOPS) [36] for the lon-
gest held occupation (categorized using quartiles of the SIOPS score distribution among
controls). The correlation between the two SES measures was low (Pearson r = 0.39).
Statistical analysis
We examined associations between cumulative BM dose and sex, age, SES and medical history
among controls (both overall and by type of control) in multivariate linear regression models.
Only medical history variables were found to be associated with cumulative BM dose and were
retained as possible confounders and included in the fully adjusted risk model.
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We estimated the association (odds ratios (OR) and 95% confidence intervals (CI)) between
lymphoma risk and cumulative medical IR dose using multivariate unconditional logistic
regression, adjusting for the matching variables (sex, age, and country), SES (categories of edu-
cation and of SIOPS) and medical condition (listed above). Linearity of the dose-response rela-
tion was evaluated using a Generalized Additive Model (GAM) by entering dose as a
continuous variable.
Sensitivity analyses were conducted by a) restricting the analysis to only hospital or only
population-based controls; b) excluding subjects reporting any history of osteoarthritis, atopic,
autoimmune or infectious disease; c) restricting analyses to participants with at least one high-
dose examination (kidney, bone X-ray or CT-scan); d) excluding subjects reporting gamma-
graphy or any additional IR procedures not included in the dose calculation; e) using a 5 year
exclusion period between dose and disease; f) using dose estimates calculated under different
assumptions related to the examination time period (above); g) excluding cases interviewed
over one year after diagnosis to minimize a potential survival bias; h) adjusting for smoking as
a potential confounder; and i) testing for homogeneity of risk between sexes. All tests were
likelihood ratio based, two-sided with a significance level of 0.05. The analysis was performed
using R version 3.3 [37] and STATA 14.0 [38].
Ethics approval
Ethics approval was obtained in 1997 from the Ethics Committee of Bellvitge hospital (coordi-
nation centre) under the project name “Eurolymph II”. Additional approval (extension of the
project, reanalysis of existing data) was obtained from the International Agency for Research
on Cancer (IARC) ethics review board (January 2010, project number 09–34). Ethics approval
was also obtained from the relevant ethics committees of the participating countries. The list
of participating institutions/hospitals can be found in S3 File. The study protocol followed was
in accordance with the ethical standards of the responsible committees on human experimen-
tation and with the Helsinki Declaration. Written consent was obtained from all participants
whose data were used in the present publication.
Results
A total of 2,362 lymphoma cases and 2,465 controls were recruited into the study. The overall
participation rates were 87.7% and 68.5% respectively for cases and controls (81.1% for hospi-
tal controls and 51.3% for population controls). The median time between diagnosis and inter-
view was 40 days (Interquartile range: 15 days; 84 days). We excluded 646 participants from
analysis who reported: a) a personal history of cancer; or b) immune-depression; or c) had
missing values in one of the basic adjustment variables (age, education or SIOPS). We also
excluded 307 participants (7.7% of controls, 6.8% of cases) for whom data were insufficient to
reconstruct their doses. A total of 1,877 cases (1599 NHL; 283 HL; 411 CLL) and 1,987 controls
were included in our analyses.
Table 2 presents the characteristics of the study population. Overall, there were more men
than women (56.6% male). Countries with the highest number of participants were Germany
(N = 1,194) and Spain (N = 933). Only 14.9% of participants had a high education level. Atopic
diseases were more prevalent in population controls, autoimmune diseases and osteoarthritis
in hospital controls, and infectious diseases in cases.
The median (Interquartile range—IQ) number of examinations excluded (because of the
two-year latency period) was 1 (0; 2) for thorax X-rays, 1 (0; 1) for CT-scans and 0 for all other
examinations (S3 Table). A total of 86.4% of cases and 92.7% of controls reported at least one
examination. Among the exposed participants, the median (IQ) cumulative BM dose was 2.25
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(0.82; 5.30) mGy; the mean (standard deviation—SD) was 3.89 (6.07) mGy. The maximum
dose was 70.98 mGy.
We explored associations between socio-demographic and medical history variables (inde-
pendent variables) and cumulative BM dose (dependent variable) among controls (Table 3).
Female controls had on average, a lower IR dose (expressed in mGy) than males (beta coeffi-
cient β = -1.77; 95% CI -2.39; -1.16). Older controls tended to have received higher doses than
Table 2. Basic characteristics of included cases and controls, Epilymph study, 1998–2004.
Hospital Controls n = 1,109 Population controls n = 878 Cases n = 1,887
n (%) or median (IQ range) n (%) or median (IQ range) n (%) or median (IQ range)
Sex
Male 618 (55.7) 490 (55.8) 1,084 (57.4)
Age continuous (years) 58 (44; 69) 59 (45; 67) 59 (44; 68)
Country
Spain 487 (43.9) - 446 (23.6)
Czech Republic 273 (24.6) - 264 (14)
France 147 (13.3) - 180 (9.5)
Germany - 588 (67) 606 (32.1)
Italy - 290 (33) 205 (10.9)
Ireland 202 (18.2) - 186 (9.9)
Education
Low 493 (44.5) 390 (44.4) 858 (45.5)
Medium 471 (42.5) 351 (40) 766 (40.6)
High 145 (13.1) 137 (15.6) 263 (13.9)
Occupational SESa
First quartile 321 (28.9) 179 (20.4) 474 (25.1)
Second quartile 360 (32.5) 273 (31.1) 585 (31)
Third quartile 211 (19) 149 (17) 367 (19.4)
Fourth quartile 217 (19.6) 277 (31.5) 461 (24.4)
Medical Historyb
Family history of lymphoma 32 (2.9) 25 (2.8) 74 (3.9)
Atopic disease 513 (46.3) 470 (53.5) 930 (49.3)
Autoimmune disease 82 (7.4) 36 (4.1) 94 (5)
Infectious disease 163 (14.7) 154 (17.5) 359 (19)
Osteoarthritis 322 (29) 129 (14.7) 335 (17.8)
Cardiovascular disease 7 (0.6) 11 (1.3) 16 (0.8)
Having at least one chronic disease 416 (37.5) 293 (33.4) 600 (31.8)
Sick childhood 173 (15.6) 121 (13.8) 223 (11.8)
Lymphoma subgroup
Hodgkin Lymphoma 283 (15)
Non Hodgkin Lymphoma 1599 (84.7)
Non Classifiable 5 (0.3)
Medical radiation exposure
Exposed subjects 1014 (91.4) 829 (94.4) 1,632 (86.4)
Bone marrow dose (mGy) 2.27 (0.8; 5.22) 3.01 (1.09; 6.58) 2.01 (0.77; 4.66)
n: numbers; IQ: interquartile range
a Standard International Occupational Prestige Scale (SIOPS);
b See methods for the definition of each medical history variable
https://doi.org/10.1371/journal.pone.0235658.t002
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younger controls (for each year of increasing age, the β was 0.03; 95% CI 0.01; 0.05). Popula-
tion controls had somewhat higher doses than hospital controls (β = 1.01, 95% CI 0.41; 1.63).
Higher cumulative BM doses were also observed among controls reporting a history of any
atopic disease (β = 1.18; 95% CI 0.59; 1.78), autoimmune disease (β = 1.65; 95% CI 0.35–2.84),
infectious disease (β = 1.14; 95% CI 0.34–1.95), or osteoarthritis (β = 1.58; 95% CI 0.82; 2.34),
and worse childhood health status (β = 1.61; 95% CI 0.85; 2.38). Thus reporting one of the dis-
eases was associated with an average increase in cumulative dose of approximately 50% with
respect to the median dose value in the overall study population. Results were similar when
stratified by type of control (Table 3).
Table 4 reports estimates of lymphoma risk in relation to medical IR dose measured as a)
never/ever exposed; b) categories of cumulative lifetime BM dose; and c) categories of total
numbers of X-rays. Dose was modeled as a categorical variable, as the results of the GAM indi-
cated the dose-response analysis may not be linear (p = 0.005). Graphical results of the GAM
are shown in S4 File.
Table 3. Associations of cumulative lifetime BM dose and demographic and medical characteristics for all controls together, population controls and hospital
controls.
All controls Population controls Hospital controls
(n = 1755) (n = 689) (n = 1066)
β a 95%CI β a 95% CI β a 95% CI
Sex
Female -1.77 -2.39; -1.16 -1.71 -2.73; -0.69 -1.81 -2.59; -1.04




Czech Republic -0.38 -1.49; 0.73
France -1.01 -2.28; 0.27
Ireland -0.51 -1.62; 0.6
Population controls 1.01 0.41; 1.63
Germany Ref
Italy -0.03 -1.06; 1.01
Education
Medium 0.1 -0.67; 0.87 0.04 -1.15; 1.22 0.21 -0.82; 1.25
High 0.43 -0.67; 1.53 0.79 -0.86; 2.44 0.25 -1.24; 1.74
SIOPS
Second quartile -0.03 -0.81; 0.76 -1.2 -2.58; 0.17 0.4 -0.55; 1.35
Third quartile 0.43 -0.48; 1.33 0.28 -1.28; 1.84 0.27 -0.84; 1.38
Fourth quartile 0.43 -0.5; 1.36 -0.21 -1.66; 1.24 0.66 -0.58; 1.89
Medical History
Family history of lymphoma 1.38 -0.37; 3.13 -0.03 -2.95; 2.9 2.29 0.1; 4.48
Atopic 1.18 0.59; 1.78 2.36 1.37; 3.34 0.5 -0.25; 1.26
Autoimmune 1.65 0.35; 2.84 1.35 -1.07; 3.77 1.64 0.2; 3.09
Infectious 1.14 0.34; 1.95 1.25 -0.01; 2.51 1.13 0.09; 2.18
Osteoarthritis 1.61 0.85; 2.38 0.65 -0.84; 2.14 2.11 1.22; 3.01
Cardiovascular disease 0.12 -0.55; 0.79 0.92 -0.18; 2.01 -0.46 -1.3; 0.38
Sick childhood 1.62 0.8; 2.44 2.17 0.8; 3.54 1.41 0.39; 2.43
aβ coefficients are mutually adjusted for the remaining model variables. β coefficients are expressed in mGy
Complete case analysis: controls with any missing data in medical history variables were excluded from analysis (n = 232);
https://doi.org/10.1371/journal.pone.0235658.t003
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Ever having had an IR diagnostic examination resulted in a reduced OR for lymphoma risk
(OR = 0.50, 95% CI 0.41–0.65). Most ORs by category of cumulative BM dose were below 1.0
in comparison with the reference category (no exposure or dose less than 1 mGy), both in the
crude and in the fully-adjusted models (Table 4). Similar results were obtained when using
measures of the BM cumulative dose estimated under the alternative exposure assumptions
(S4 Table) and using a 5-year exclusion period (Table 5). Stronger inverse associations were
observed in analyses based on categories of total numbers of examinations compared to analy-
ses by categories of doses (Table 4). Results of analysis by subtype of lymphoma (HL, NHL,
lymphoma excluding CLL, and CLL only) are presented in Table 5. Overall, a similar pattern
of reduced ORs was found for each lymphoma subtypes, however for HL the evidence of a
decrease trend is not statistically significant.
Findings were similar when restricting analyses to population or to hospital controls
(Table 5). When we restricted the analysis to subject who did not report any chronic diseases
there was no longer evidence of a dose-related inverse trend, with the OR in the highest dose
category being close to 1.0. Similar results were obtained when additionally restricting to pop-
ulation controls, though the sample size was small (6 cases and 8 controls with dose>15 mGy)
(Table 5). In further sensitivity analyses including only subjects who reported at least one high
dose examination (CT-scan, kidney or bone X-ray) the strength of the inverse association
weakened and none of the categorical ORs were statistically significantly different from 1.0
(Table 5). When we excluded subjects (N = 1,094) who reported any gammagraphy or any
additional IR examination as free text, results were similar to those of the main analyses
(Table 5). Risk estimates did not change when excluding the 76 cases interviewed more than
one year after diagnosis, to minimize a possible effect of survival bias. Adjusting for smoking
status (ever/never) did not change the results and we had no evidence for heterogeneity of risk
by sex (p = 0.94, not shown).
Table 4. Associations of BM IR dose and lymphoma risk (odds ratio and 95% confidence intervals) (n = 3,424).
Controls Cases Basic Model Fully-adjusted Model
OR 95% CI OR 95% CI
None 133 227 Ref Ref
Any Procedures 1625 1439 0.51 0.40; 0.64 0.51 0.41; 0.65
Bone Marrow dose categorya
0-<1 mGy 586 659 Ref Ref
1-<5 mGy 710 679 0.83 0.71; 0.97 0.84 0.71; 0.98
5- <15 mGy 374 267 0.61 0.50; 0.74 0.62 0.50; 0.76
�15 mGy 88 61 0.60 0.42; 0.85 0.63 0.44; 0.9
P for trend <0.001 <0.001
Number of X-rays
None 133 227 Ref Ref
1–4 X-ray 465 464 0.57 0.45; 0.74 0.58 0.45; 0.75
5–14 X-rays 638 608 0.54 0.42; 0.69 0.55 0.43; 0.7
>15 X-rays 522 367 0.39 0.30; 0.50 0.39 0.30; 0.51
P for trend <0.001 <0.001
Unconditional logistic regression model. Basic model is adjusted for sex, age, country and SES variables. Fully adjusted model is adjusted also for positive medical
history of atopic, autoimmune, or infectious disease or osteoarthritis and/or sick childhood. Complete case analysis: participants with any missing data in medical
history variables were excluded from analysis (n = 440).
a The mean dose between the first and last exposure was attributed to the “n-2” examinations. See methods for details. Mean dose value in each dose category: 0.33 mGy
[0-<1 mGy]; 2.59 mGy [1-<5 mGy]; 8.31 mGy [5-<15 mGy]; 25.23 mGy [�15 mGy]. Maximum dose in�15mGy category is 70.98 mGy.
https://doi.org/10.1371/journal.pone.0235658.t004
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Table 5. Cumulative lifetime BM dose from common radio-diagnostic examination and lymphoma risk estimates (odds ratio and 95% confidence intervals) by sub-
type of lymphoma, type of control, disease status, time between interview and diagnosis, type of examination, using a 5 year exclusion period and adjusting for
smoking status.
BM Dose categorya Controls Cases Adjusted OR 95% CI Controls Cases Adjusted OR 95% CI
A. Hodgkin lymphoma (2009) B. Non Hodgkin lymphoma (3168)
0-<1 mGy 586 139 Ref 586 518 Ref
1-<5 mGy 710 78 0.71 0.51; 0.99 710 598 0.88 0.74; 1.04
5- <15 mGy 374 27 0.54 0.33; 0.87 374 240 0.64 0.51; 0.79
�15 mGy 88 7 0.85 0.36; 2.02 88 54 0.62 0.43; 0.91
P for trend 0.16 <0.001
C. All lymphoma, excluding CLL (3418) D. Only CLL (2098)
0-<1 mGy 586 555 Ref 586 104 Ref
1-<5 mGy 710 522 0.80 0.68; 0.95 710 157 1.03 0.78; 1.39
5- <15 mGy 374 198 0.58 0.47; 0.72 374 69 0.77 0.53; 1.39
�15 mGy 88 51 0.68 0.46; 0.99 88 10 0.48 0.24; 1.01
P for trend 0.001 0.014
E. Only population controls (1338) F. Only hospital controls (2106)
0-<1 mGy 200 227 Ref 386 432 Ref
1-<5 mGy 277 243 0.76 0.58; 0.99 433 436 0.87 0.72; 1.06
5- <15 mGy 172 128 0.63 0.46; 0.86 202 139 0.61 0.46; 0.79
�15 mGy 42 32 0.68 0.40; 1.14 46 29 0.62 0.38; 1.02
P for trend 0.05 0.002
G. Participants reporting no disease (904)a H. Participants reporting at least one disease (2970)b
0-<1 mGy 171 223 Ref 415 436 Ref
1-<5 mGy 152 146 0.73 0.54; 0.98 558 533 0.87 0.73; 1.03
5- <15 mGy 61 45 0.53 0.35; 0.81 313 222 0.63 0.51; 0.78
�15 mGy 6 8 0.98 0.33; 2.74 82 53 0.56 0.40; 0.80
P for trend 0.07 < 0.001
I. Population controls and participants reporting no disease (589) b J. Excluding cases with an interval between diagnosis and interview
larger than 1 year (exclusion of 76 cases)
0-<1 mGy 63 88 Ref 586 634 Ref
1-<5 mGy 61 56 0.71 0.49; 1.03 710 654 0.84 0.71; 0.98
5- <15 mGy 26 27 0.70 0.44; 1.13 374 259 0.63 0.51; 0.77
�15 mGy 2 5 0.92 0.34; 2.57 88 58 0.63 0.44; 0.91
P for trend 0.68 <0.001
K. Excluding participants not reporting any CT-scan, kidney or
bone X-ray (2209)
L. Excluding subjects who reported gammagraphy or other
examination in free text (2416)
0-<1 mGy 195 160 Ref 461 476 Ref
1-<5 mGy 563 511 1.07 0.83; 1.37 520 492 0.90 0.75; 1.08
5-<15 mGy 362 255 0.82 0.62; 1.08 219 160 0.69 0.53; 0.89
�15 mGy 88 60 0.80 0.53; 1.20 55 33 0.60 0.38; 0.96
P for trend 0.04 0.002
M. Lymphoma risk using a 5 year lag- period N. Adjustment for smoking status (ever/never)
0-<1 mGy 693 737 Ref 586 659 Ref
1-<5 mGy 798 680 0.88 0.75; 1.01 710 679 0.83 0.70; 0.97
5- <15 mGy 291 211 0.66 0.53; 0.88 374 267 0.61 0.50; 0.74
�15 mGy 67 45 0.65 0.43; 0.97 88 61 0.62 0.43; 0.89
(Continued)
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Discussion
We estimated the cumulative IR BM dose from the most common radiological examinations
reported in the large multinational Epilymph study. IR doses tended to be very low (median
2.25 mGy), of the order of one year of natural background radiation on average [39], with
none of the subjects exceeding 100 mGy. We found no increased risk of lymphoma from IR
exposure from common self-reported medical radiological procedures. Indeed, ORs were gen-
erally<1.0 when comparing each exposure category to the reference category (no exposure/
exposure less than 1 mGy), possibly reflecting unmeasured confounding, an unidentified
source of systematic bias, or chance, considering the low statistical power of the study.
Selection bias
Selection bias arises if participation is related to the exposure of interest. Hospital controls may
have been suffering from a chronic disease (and were possibly more likely to have undergone
medical IR): this could explain the higher levels of exposure among controls and the reduced
ORs for lymphoma risk (S5 File). However, analyses by type of controls showed similar results
and we saw no substantial difference in disease prevalence between population and hospital
controls. Population controls also had a higher BM dose when compared to controls recruited
in the hospital. Participation rates were lower among controls compared to cases, particularly
among population controls. It is possible that the controls who participated represent a popu-
lation receiving a different type of medical attention (i.e. controls who were more worried
about their health or with poorer general health may be more likely to participate in a medical
research study) than the population from which they were drawn. Indeed, when excluding
subject reporting any chronic disease, we didn’t found evidence of a decrease trend.
Confounding
The aetiology of lymphoma is complex, and putative risk factors may not be consistently asso-
ciated across all lymphoma subtypes [22]. We adjusted all our analysis for family history,
which has been found to be the most consistent risk factor across all NHL subtypes [22].
Chronic diseases may also be relevant confounders as they are associated with both diagnostic
IR exposure and lymphoma risk (S5 File). A negative association between lymphoma and
atopic, autoimmune and osteoarthritis has been reported [22, 23] and this could explain our
inverse ORs. The association between medical conditions and lymphoma risk has been evalu-
ated in the Epilymph study [25, 40], with reduced OR observed for allergies, osteoarthritis, dia-
betes, and those reporting to have been “more sick than siblings during childhood”.
Table 5. (Continued)
BM Dose categorya Controls Cases Adjusted OR 95% CI Controls Cases Adjusted OR 95% CI
P for trend 0.001 <0.001
Unconditional logistic regression models adjusted for matching variables, SES, family history of lymphoma and medical history positive to atopic, autoimmune,
infectious, osteoarthritis and/or sick childhood. All models are fully-adjusted with the exception of model E, F, G, H, and I which are adjusted for matching variables
and SES.
Participants with any missing data in medical history variables were excluded from analysis.
Dose category based on the second scenario assumption.
a Mean dose value in each dose category: 0.33 mGy [0-<1 mGy]; 2.59 mGy [1-<5 mGy]; 8.31 mGy [5-<15 mGy]; 25.23 mGy [�15 mGy]. Maximum dose in�15mGy
category is 70.98 mGy.
bDisease categories are: atopic, autoimmune, osteoarthritis and infectious diseases.
https://doi.org/10.1371/journal.pone.0235658.t005
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Subject who reported any atopic, autoimmune, or infectious disease as well as osteoarthritis
had a higher average estimated BM dose, as did participants with poorer health during child-
hood. This higher dose is expected as such diseases may require radio-diagnostic evaluation.
Although we were unable to explore the potential impact of chronic disease in depth here,
as the medical reason/indication for the diagnostic procedure was not available, we adjusted
analyses for atopic, autoimmune, osteoarthritis, infectious, and childhood diseases. This did
not change the risk estimates, neither did excluding subjects who reported any chronic disease
(atopy, autoimmune, infectious disease or osteoarthritis). However, as information on medical
history was self-reported and may be subject to recall bias, adjustment may not be adequate.
We adjusted for socioeconomic status, as it has been reported that the exposure to medical
ionizing radiation may be related to the socioeconomic status [41]. Again, adjustment did not
change results, however we may not fully capture the socioeconomic status of the subject, as
we measured it with proxies (occupational SIOPS score, education level).
Uncertainty in the dose estimation
For the individual dose estimation, we had limited data on lifetime radiological history, leading
to uncertainties in dose estimates. First, we lacked information on the exact time period and
age at each procedure. In general, doses have decreased in recent time periods, especially in
younger patients as a result of increased awareness and optimization [29, 42]. To address this,
we developed three exposure scenarios with different assumptions regarding the timing of
examinations; sensitivity analyses using the two alternative scenarios showed that these
assumptions did not influence our risk estimates.
X-ray procedures were defined in broad terms in the questionnaire. The advantage of using
such broad, generic terms is to make the questions shorter and simpler. However, when recon-
structing dose, it is a major source of uncertainty since doses could vary substantially depend-
ing on the anatomical region examined. Reported BM doses from the most common CT-scan
type performed in adults can vary between 6.9 mGy (chest CT-scan), 3 mGy (abdomen CT-
scan) and 1.3 mGy (head CT-scan) [30]. As no information on body part was specified for CT-
scans, we used a weighted average considering the distribution of body part scanned in differ-
ent age groups (for adults we attributed 3.32 mGy to each CT-scan). Thus, in adults we have
potentially overestimated the dose for 40% of the procedures (head CT-scans) and underesti-
mated it for 30% (chest CT-scan). However, the percentage of participants who reported a CT
scan is low (18%) and the body-part uncertainty is unlikely to be differential between cases
and controls.
Furthermore, our cumulative BM dose estimation does not include all types of medical
radiological procedures, only the most common. Misclassification due to the omission of
other radiological procedures cannot be excluded. To further address this issue, we excluded
subjects who reported a previous tumor because they may have received radiotherapy. In a
sensitivity analysis, we also excluded subjects reporting gammagraphy and additional proce-
dures (reported as free text) with no change in ORs. However, differential misclassification
due to omission of uncommon radiological procedures, though unlikely to affect a large pro-
portion of the population, cannot be excluded if controls (in particular hospital controls) were
more likely to have undergone procedures not considered here, due to specific underlying
chronic medical conditions.
Finally, the choice of BM as the target organ may also lead to uncertainty as it may be inade-
quate for some lymphoma subtypes: all lymphoid cells originate in the BM, however, their dif-
ferentiation occurs only partially in the BM and, in adults, forms of lymphomas that arise from
peripheral cells are more frequent [43]. However, in radiation epidemiology, BM is
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traditionally accepted as the target organ for lymphomas and leukemia and using it allows
comparisons with the published literature. Although some studies have used alternative target
organ doses, for example mean lymphocyte dose in a study of pediatric CT-scans [14], we
were limited by the available information in the study. [14].
Exposure information bias
This study is based on self-reported data and it was not possible to check medical records to
validate responses. The informed consent signed by the participants allowed the researchers to
access medical records only in the hospital where they were recruited, and hence we are unable
to validate all of the procedures reported by the patient. In addition, considering the age range
of the participants, most of the procedures (in particular those performed in childhood) are
likely to have been recorded in paper charts, not in electronic medical records, thus making
them very difficult to access. A medical records review that cannot assess the complete lifetime
diagnostic exposure of the subjects would be difficult to interpret [44].
As we based our analyses on self-reported medical radiological history, recall error (random
and systematic, differential or not between cases and controls) is likely. Previous studies have
attempted to estimate the impact of recall bias when collecting medical radiological history [44–
46]. Dreger et al. (2015) found evidence of underreporting in older populations and of over-
reporting of CT-scans possibly due to confusion with Magnetic Resonance Imaging (MRI), how-
ever comparison was only for recent procedures (not covering the entire lifetime of the study sub-
jects), thus the measurement error in our study may be greater. Berrington et al. [44] reported
substantial disagreement between medical record based and self-reported medical radiological
history. Such disagreement was shown to be independent of sex, age at interview, time since
exposure and calendar year at exposure. Disagreement was also non-differential between cases
and controls. However, the accuracy of reporting tended to decrease with increasing number of
procedures reported in medical records. The study also compared risk estimates of thyroid cancer
from medical IR using information from medical records with risk estimates based on self-
reported information; no substantial difference in risk estimates was observed. Similarly, Pogoda
et al. [45] did not report important differences when comparing acute myeloid leukemia risk
from medical diagnostic IR exposure based on medical records or self-reported.
Even when non-differential between cases and controls, recall error can affect risk esti-
mates, though the direction of the effect is unpredictable [47]. The observed reduced ORs in
our analyses may be partially explained by non-differential misclassification, if the misclassifi-
cation occurs between the higher and the lower dose categories [48]. Individuals with higher
dose may have been classified as non-exposed simply because they failed to report a single
high dose examination (CT-scan) or if they underwent other high dose examinations that
weren´t considered in the present study. An individual with no radiation exposure could also
be classified as highly exposed if diagnostic procedures that do not involve IR (e.g. magnetic
resonance imaging, ultrasound) were confused with X-ray procedures (CT-scan, other X-
rays). Participants with chronic diseases may also have greater misclassification as they may be
a sub-group that receives more “uncommon” radiological examinations (categorized as unex-
posed, but truly high exposed), or non-IR diagnostic examination (magnetic resonance imag-
ing) that may be confused with CT-scans. In this sense, the analyses excluding subjects who
reported the medical conditions considered should be less affected by potential non-differen-
tial misclassification. Such analysis did not shown a decrease trend.
Our findings could also be explained by a tendency of controls to over-report or a tendency
among cases to under-report the number of procedures, however, such differential bias has
not previously been reported in similar studies [44, 45].
PLOS ONE Medical x-rays exposure and lymphoma risk in Epilymph study
PLOS ONE | https://doi.org/10.1371/journal.pone.0235658 July 10, 2020 14 / 19
Reverse causation bias
In our analysis, we could not specifically identify examinations taken for the lymphoma diag-
nosis, and including them may lead to reverse causation bias. To avoid this, we excluded all
examinations taken in the two years prior to diagnosis/reference date. The median number of
excluded examinations in cases is in line with the number of examinations required for a lym-
phoma diagnosis (S3 Table), which is normally one CT-scan and one thoracic X-ray [49]. In
addition, if reverse causation bias had an impact on cases, we would have expected a positive
bias in ORs. Further, since analysis stratified by type of controls lead to similar results, it is
unlikely that our risk estimates were affected by hospital controls possibly receiving medical
X-rays during hospitalization.
Statistical power
To our knowledge, this is the largest case-control study evaluating medical IR exposure and
subsequent lymphoma risk. However, the doses estimated were very low and hence the statisti-
cal power was limited to detect the small increase in risk that might be expected, based on cur-
rent radiation risk estimates, from such dose levels. In addition, the literature review approach
to exposure assignment could have introduced Berkson error [50], as we attributed exposure
based on average dose values by time period, likely to further reduce the statistical power of
the study. Analyses by sub-type of lymphoma were based on lower numbers and hence had
even lower power. In our analysis, however, the ORs for NHL, CLL, and excluding CLL all
showed similar and consistent reduced risks.
Our results should be interpreted in the context of the literature of lymphoma risk after
exposure to medical diagnostic IR. The low study power and low exposure level makes it diffi-
cult for our study to reach adequate conclusions.
Conclusion
We found no positive association between categories of cumulative lifetime BM dose (or num-
ber of procedures) from common medical diagnostic procedure and risk of lymphoma. Over-
all the doses were very low, thus we would have expected no increased risk or at most a very
small increased risk. The reduced ORs observed here may be explained by some methodologi-
cal bias we have been unable to identify, to residual confounding, or to chance. Future studies
will benefit from collection of additional information on the time period, body part and the
reason for each examination to overcome such possible uncertainties. Information on medical
conditions should also be collected together with radiological history, given their potential
confounding effect. Control selection should also aim to reduce possible participation biases
related to previous medical history and therefore diagnostic IR exposure.
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